Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
35 results
D2.127 - Rhinovirus Infection in Early Childhood and Risk of Asthma: A Two-Year Follow-Up Study
D2.122 - Impact of Asthma on Outcomes after out-of-hospital cardiac arrest: A nationwide pathway-based analysis, 2013-2023
D2.123 - Temporal Stability of Asthma-Related Out-of-Hospital Cardiac Arrest: A Nationwide SARIMA Analysis of Korean Data From 2013 to 2023
D2.124 - Clinical Significance of Humoral Immunodeficiency in Patients with Severe Asthma
D2.125 - When Severe Asthma Isn’t Asthma: A Case of Humoral Immunodeficiency With Suspicion of Lymphoproliferative Disease
D2.126 - Analysis of Clinical Characteristics and Airway Morphological Structure Parameters in Patients with Bronchial Asthma Combined with Bronchiectasis
D2.129 - Cardiac onset of EGPA in a postpartum woman: the importance of early diagnosis
D2.130 - Dupilumab for asthma and chronic rhinosinusitis with or without nasal polyps : A Multi-Timepoint Real-World Analysis
D2.131 - Application of a Neural Network Model for Predicting Clinical Outcomes of Acute Bronchitis with Bronchospasm Based on Comorbidities
D2.132 - Prediction of Clinical Outcomes of Acute Bronchitis with Bronchospasm Based on Trigger Factors Using a Neural Network Model
D2.133 - Assessment of growth pattern in wheezing children (3-12 years of age)
D2.449 - Patients with Inadequately Controlled CRSwNP and Blood Eosinophil Count ≥150 cells/µL Experience Benefit with Depemokimab: An Analysis of Data from the Integrated ANCHOR-1/-2 Studies
D2.447 - Phenotyping of Chronic T2 Inflammatory Diseases of the Nose and Paranasal Sinuses and the Algorithm for Biologic Therapy Selection
D2.448 - Recommendations on Patient Education for Biological Therapy in CRSwNP – An EAACI Position Paper
D2.450 - EUFOREA/EPOS Criteria Applied to a Diverse CRSwNP Cohort: Post Hoc Findings from Twice-Yearly depemokimab ANCHOR-1/-2 trials
D2.451 - Real-life upper and lower airway outcomes of long-term dupilumab treatment in patients with severe chronic rhinosinusitis with nasal polyps
D2.452 - Real-World Trends in the Epidemiology and Burden of Chronic Rhinosinusitis with Nasal Polyps Over Time in Germany Reveal Increasing Prevalence and Low Biologic Use
D2.453 - Olfactory outcomes of dupilumab in patients with CRSwNP: A real-world prospective study
D2.455 - Does Biological Therapy Modify NSAID Hypersensitivity? Experience with Omalizumab and Mepolizumab in Patients with Asthma and Nasal Polyps with N-ERD
D2.456 - Chronic sinusitis with nasal polyposis: Add-on aspirin desensitization useful in dupilumab therapy?
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download